甜甜小
06-10
在创新药投资中,高风险常被挂在嘴边,看了下维立志博的几个管线,安全性优势很突出,这对后续商业化至关重要,毕竟医生更愿意用副作用小的药,在管线布局上,也都踩在临床刚需和竞争较少的痛点上,这点还是不错的
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":444462053658920,"tweetId":"444462053658920","gmtCreate":1749532544797,"gmtModify":1749533016597,"author":{"id":4130491029501360,"idStr":"4130491029501360","authorId":4130491029501360,"authorIdStr":"4130491029501360","name":"甜甜小","avatar":"https://static.tigerbbs.com/25fc231df4362a5cdc318177a8de3233","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body>在创新药投资中,高风险常被挂在嘴边,看了下维立志博的几个管线,安全性优势很突出,这对后续商业化至关重要,毕竟医生更愿意用副作用小的药,在管线布局上,也都踩在临床刚需和竞争较少的痛点上,这点还是不错的</body></html>","htmlText":"<html><head></head><body>在创新药投资中,高风险常被挂在嘴边,看了下维立志博的几个管线,安全性优势很突出,这对后续商业化至关重要,毕竟医生更愿意用副作用小的药,在管线布局上,也都踩在临床刚需和竞争较少的痛点上,这点还是不错的</body></html>","text":"在创新药投资中,高风险常被挂在嘴边,看了下维立志博的几个管线,安全性优势很突出,这对后续商业化至关重要,毕竟医生更愿意用副作用小的药,在管线布局上,也都踩在临床刚需和竞争较少的痛点上,这点还是不错的","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/444462053658920","repostId":0,"isVote":1,"tweetType":1,"viewCount":224,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":190,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/444462053658920"}
精彩评论